{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:11:22Z","timestamp":1794625882353,"version":"4.9.1"},"reference-count":207,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurol.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T11:02:21Z","timestamp":1734865341000},"page":"265-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-8021","authenticated-orcid":false,"given":"D.","family":"Amstutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-6435","authenticated-orcid":false,"given":"M.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Maradan-Gachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Debove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lhomm\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1000","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","article-title":"Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms","volume":"8","author":"Rodriguez-Oroz","year":"2009","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jnnp.2006.100073","article-title":"Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia","volume":"78","author":"Bohnen","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","article-title":"Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches","volume":"21","author":"Bohnen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mds.26587","article-title":"Emotional manifestations of PD: neurobiological basis","volume":"31","author":"Castrioto","year":"2016","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1025","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jagp.2019.03.002","article-title":"The neuropsychiatry of Parkinson disease: a perfect storm","volume":"27","author":"Weintraub","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1035","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov Disord"},{"issue":"15","key":"10.1016\/j.neurol.2024.11.004_bib1040","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/mds.23394","article-title":"What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?","volume":"25","author":"Gallagher","year":"2010","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","article-title":"Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease","volume":"21","author":"Martinez-Martin","year":"2015","journal-title":"Park Relat Disord"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1474-4422(06)70476-8","article-title":"Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study","volume":"5","author":"Iranzo","year":"2006","journal-title":"Lancet Neurol"},{"issue":"9680","key":"10.1016\/j.neurol.2024.11.004_bib1060","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1065","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/mds.870070203","article-title":"When did Ray Kennedy's Parkinson's disease begin?","volume":"7","author":"Lees","year":"1992","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JPD-150685","article-title":"The concept of prodromal Parkinson's disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1080","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.24921","article-title":"Lewy pathology and neurodegeneration in premotor Parkinson's disease","volume":"27","author":"Del Tredici","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2024.11.004_bib1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1353-8020(13)00400-8","article-title":"Prodromal Parkinson's disease - using REM sleep behavior disorder as a window","volume":"20","author":"Postuma","year":"2014","journal-title":"Park Relat Disord"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.2258","article-title":"Comparison between four published definitions of hyposmia in Parkinson's disease","volume":"11","author":"Kanavou","year":"2021","journal-title":"Brain Behav"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13411-014-0030-9","article-title":"Neuroenology: how the brain creates the taste of wine","volume":"4","author":"Shepherd","year":"2015","journal-title":"Flavour"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/mdc3.12454","article-title":"Autonomic dysfunction in early Parkinson's disease: results from the United Kingdom tracking Parkinson's study","volume":"4","author":"Malek","year":"2017","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case-control study","volume":"14","author":"Schrag","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1474-4422(15)00396-8","article-title":"Joy of super smeller: sebum clues for PD diagnostics","volume":"15","author":"Morgan","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ana.26085","article-title":"Speech biomarkers in rapid eye movement sleep behavior disorder and Parkinson disease","volume":"90","author":"Rusz","year":"2021","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2024.11.004_bib1120","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.27802","article-title":"Update of the MDS research criteria for prodromal Parkinson's disease","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.43.3_Part_1.505","article-title":"Dopamine-related personality traits in parkinson's disease","volume":"43","author":"Menza","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mds.870100211","article-title":"A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients","volume":"10","author":"Glosser","year":"1995","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1135","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/brain\/awp094","article-title":"Reward-learning and the novelty-seeking personality: a between-and within-subjects study of the effects of dopamine agonists on young parkinsons patients","volume":"132","author":"B\u00f3di","year":"2009","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1034\/j.1600-0404.2001.103002082.x","article-title":"Personality traits in young patients with Parkinson's disease","volume":"103","author":"Jacobs","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2024.11.004_bib1145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jnnp.48.2.97","article-title":"The pre-morbid personality of patients with Parkinson's disease","volume":"48","author":"Todes","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.10277","article-title":"A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease","volume":"52","author":"Hern\u00e1n","year":"2002","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1155","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch Neurol"},{"issue":"16","key":"10.1016\/j.neurol.2024.11.004_bib1160","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1212\/WNL.0000000000000879","article-title":"Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease","volume":"83","author":"Ritz","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp.2005.065417","article-title":"Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease","volume":"77","author":"Evans","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Ann Neurol"},{"issue":"1\u20133","key":"10.1016\/j.neurol.2024.11.004_bib1175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0014-2999(99)00888-2","article-title":"Nicotinic receptors and Parkinson's disease","volume":"393","author":"Quik","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"39","key":"10.1016\/j.neurol.2024.11.004_bib1180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-neuro-070815-013920","article-title":"The emergence of a circuit model for addiction","volume":"8","author":"L\u00fcscher","year":"2016","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1185","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.neurol.2024.11.004_bib1190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jnnp-2022-330790","article-title":"Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia","volume":"94","author":"Costello","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.11.004_bib1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson's disease: a systematic review and meta-analysis of 129 studies","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/mds.23092","article-title":"Depression and the subsequent risk of Parkinson's disease in the NIH-AARP diet and health study","volume":"25","author":"Fang","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2024.11.004_bib1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0272315","article-title":"Depressive symptoms before and after Parkinson's diagnosis\u00a0\u2014\u00a0a longitudinal analysis","volume":"17","author":"Song","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jnnp-2020-324266","article-title":"Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study","volume":"92","author":"Kazmi","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1215","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.22833","article-title":"Anxiety disorders in Parkinson's disease: prevalence and risk factors","volume":"25","author":"Dissanayaka","year":"2010","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1220","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","article-title":"The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease","volume":"80","author":"Aarsland","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1225","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1230","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3233\/JPD-213116","article-title":"Fatigue in de novo Parkinson's disease: expanding the neuropsychiatric triad?","volume":"12","author":"B\u00e9reau","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1235","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/mds.27461","article-title":"Fatigue in Parkinson's disease: a systematic review and meta-analysis","volume":"33","author":"Siciliano","year":"2018","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1240","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/cells12121599","article-title":"Apathy in Parkinson's disease: clinical patterns and neurobiological basis","volume":"12","author":"B\u00e9reau","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/08919887231195220","article-title":"Minor phenomena in Parkinson's disease\u00a0\u2013\u00a0prevalence, associations, and risk of developing psychosis","volume":"37","author":"Schneider","year":"2023","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1255","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","article-title":"Feeling of presence in Parkinson's disease","volume":"82","author":"F\u00e9nelon","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1260","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.parkreldis.2013.11.017","article-title":"Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease","volume":"20","author":"Pagonabarraga","year":"2014","journal-title":"Park Relat Disord"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/jnnp-2019-322702","article-title":"Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management","volume":"91","author":"O\u2019brien","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ane.13555","article-title":"Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: a preliminary study","volume":"145","author":"Sumi","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1275","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1474-4422(23)00426-X","article-title":"Medical nemesis 50 years on","volume":"22","author":"Lees","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1280","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00415-018-8817-8","article-title":"Patient experiences of receiving a diagnosis of Parkinson's disease","volume":"265","author":"Schrag","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1285","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10010","article-title":"Factors impacting on quality of life in Parkinson's disease: results from an international survey","volume":"17","author":"Findley","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2024.11.004_bib1290","series-title":"On death and dying","author":"K\u00fcbler-Ross","year":"1997"},{"key":"10.1016\/j.neurol.2024.11.004_bib1295","series-title":"On grief and grieving: finding the meaning of grief through the five stages of loss","author":"K\u00fcbler-Ross","year":"2005"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1300","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JPD-181462","article-title":"Shame in Parkinson's disease: a review","volume":"9","author":"Angulo","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1305","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/gps.4834","article-title":"Efficacy and tolerability of antidepressants in Parkinson's disease: a systematic review and network meta-analysis","volume":"33","author":"Mills","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2024.11.004_bib1310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2021.793804","article-title":"Efficacy of cognitive behavioral therapy on mood disorders, sleep, fatigue, and quality of life in Parkinson's disease: a systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1315","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp.2006.098327","article-title":"A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis","volume":"78","author":"Grosset","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized delayed-start trial of levodopa in Parkinson's disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1325","first-page":"1","article-title":"\u2018Levodopa Phobia\u2019: a review of a not uncommon and consequential phenomenon","volume":"4","author":"Titova","year":"2018","journal-title":"npj Park Dis"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1330","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/mds.26712","article-title":"Unmasking levodopa resistance in Parkinson's disease","volume":"31","author":"Nonnekes","year":"2016","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1335","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: From clinical and neuropsychological characterisation to management and long-term outcome","volume":"85","author":"Cilia","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1340","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/brain\/awaa181","article-title":"Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa","volume":"143","author":"Cilia","year":"2020","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","article-title":"Parkinson disease, the effect of levodopa, and the ELLDOPA trial","volume":"56","author":"Fahn","year":"1999","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1350","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1355","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/mds.27436","article-title":"Crime and Parkinson's: the jury is out","volume":"33","author":"Santens","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1360","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/PL00007725","article-title":"Cognitive deficits in Parkinson's disease","volume":"244","author":"Dubois","year":"1996","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1370","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","article-title":"Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease","volume":"9","author":"Kehagia","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1375","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1380","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11065-021-09502-7","article-title":"Meta-analysis of cognition in Parkinson's cisease mild cognitive impairment and dementia progression","volume":"32","author":"Wallace","year":"2022","journal-title":"Neuropsychol Rev"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1385","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1212\/WNL.32.5.567","article-title":"Tip-of-the-tongue\u201d phenomenon in Parkinson disease","volume":"32","author":"Matison","year":"1982","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1390","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1395","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00702-019-02003-1","article-title":"Mild cognitive impairment in Parkinson's disease","volume":"126","author":"Martinez-Horta","year":"2019","journal-title":"J Neural Transm"},{"issue":"13","key":"10.1016\/j.neurol.2024.11.004_bib1400","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Cognitive impairment in incident, untreated parkinson disease: the Norwegian parkwest study","volume":"72","author":"Aarsland","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1405","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1212\/WNL.46.2.329","article-title":"Testing cognition may contribute to the diagnosis of movement disorders","volume":"46","author":"Pillon","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1410","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F","article-title":"Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients","volume":"15","author":"Kulisevsky","year":"2000","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1415","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WAD.0000000000000088","article-title":"Onset of mild cognitive impairment in Parkinson disease","volume":"30","author":"Johnson","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1420","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3932(03)00117-9","article-title":"L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease","volume":"41","author":"Cools","year":"2003","journal-title":"Neuropsychologia"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1425","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JPD-225064","article-title":"The early treatment phase in Parkinson's disease: not a honeymoon for all, not a honeymoon at all?","volume":"13","author":"Alonso-Canovas","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2024.11.004_bib1430","series-title":"Awakenings","author":"Sacks","year":"1973"},{"issue":"10","key":"10.1016\/j.neurol.2024.11.004_bib1435","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.neurol.2010.07.006","article-title":"Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment","volume":"166","author":"Thobois","year":"2010","journal-title":"Rev Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1440","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JPD-150535","article-title":"Apathy and impulse control disorders: Yin & yang of dopamine dependent behaviors","volume":"5","author":"Sierra","year":"2015","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-019-0013-5","article-title":"Neurobiology and clinical features of impulse control failure in Parkinson's disease","volume":"1","author":"B\u00e9reau","year":"2019","journal-title":"Neurol Res Pract"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1450","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.26164","article-title":"Changing gears\u2013DBS for dopaminergic desensitization in Parkinson's disease?","volume":"90","author":"Weiss","year":"2021","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1455","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neurol.2018.07.005","article-title":"Hyperdopaminergic behavioral spectrum in Parkinson's disease: a review","volume":"174","author":"B\u00e9reau","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.11.004_bib1460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0245142","article-title":"Personality dimensions of patients can change during the course of Parkinson's disease","volume":"16","author":"Boussac","year":"2021","journal-title":"PLoS One"},{"issue":"55","key":"10.1016\/j.neurol.2024.11.004_bib1465","first-page":"1","article-title":"Dopamine and the biology of creativity: lessons from Parkinson's disease","volume":"5","author":"Lhomm\u00e9e","year":"2014","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1470","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1475","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2020.1806059","article-title":"\u201cDopamine agonist phobia\u201d in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine","volume":"20","author":"Rota","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1480","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acn3.51022","article-title":"Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease","volume":"7","author":"Weintraub","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1485","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ene.12646","article-title":"Impulse control disorders in Parkinson's disease: don\u2019t set your mind at rest by self-assessments","volume":"22","author":"Baumann-Vogel","year":"2015","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1490","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.27689","article-title":"Scales to assess impulsive and compulsive behaviors in Parkinson's disease: critique and recommendations","volume":"34","author":"Evans","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2024.11.004_bib1495","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.irn.2017.04.001","article-title":"Measurement of nonmotor symptoms in clinical practice","author":"Martinez-Martin","year":"2017"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1500","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1505","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41386-019-0448-y","article-title":"Sleep in Parkinson's disease","volume":"45","author":"Stefani","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1510","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson's disease: the quintessential neuropsychiatric disorder","volume":"26","author":"Weintraub","year":"2011","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1515","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1520","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00002018-200225070-00001","article-title":"\u201cSleep attacks\u201d or \u201cunintended sleep episodes\u201d occur with dopamine agonists: is this a class effect?","volume":"25","author":"Chaudhuri","year":"2002","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1525","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp.2009.186874","article-title":"Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease","volume":"82","author":"O'Sullivan","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"68","key":"10.1016\/j.neurol.2024.11.004_bib1530","first-page":"1","article-title":"Sleep in Parkinson's disease with impulse control disorder","volume":"18","author":"Figorilli","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1535","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","article-title":"Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease","volume":"87","author":"Smith","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2024.11.004_bib1540","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1545","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","article-title":"Impulse control disorders in Parkinson's disease","volume":"125","author":"Marques","year":"2018","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1550","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1555","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","article-title":"Impulse control disorders in Parkinson's disease","volume":"176","author":"Weintraub","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1560","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mdc3.13156","article-title":"Reckless generosity, Parkinson's disease and dopamine: a case series and literature review","volume":"8","author":"Amstutz","year":"2021","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1565","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neurol.2018.07.009","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study in Morocco","volume":"175","author":"El Otmani","year":"2019","journal-title":"Rev Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1570","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.parkreldis.2007.04.006","article-title":"The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?","volume":"14","author":"Avanzi","year":"2008","journal-title":"Park Relat Disord"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1575","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1212\/WNL.0000000000007942","article-title":"Impulse control disorders in Parkinson disease and RBD: a longitudinal study of severity","volume":"93","author":"Baig","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1580","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","article-title":"Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease","volume":"84","author":"Eusebio","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.neurol.2024.11.004_bib1585","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?","volume":"2","author":"Lawrence","year":"2003","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1590","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/mp.2009.95","article-title":"Insights into pathophysiology of punding reveal possible treatment strategies","volume":"15","author":"Fasano","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1595","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/mdc3.12671","article-title":"The outcome of dopamine dysregulation syndrome in Parkinson's disease: a retrospective postmortem study","volume":"5","author":"Barbosa","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1600","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1605","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/mdc3.13748","article-title":"Punding in Parkinson's disease: an update","volume":"10","author":"Rajalingam","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1610","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.wco.0000137528.23126.41","article-title":"Dopamine dysregulation syndrome in Parkinson's disease","volume":"17","author":"Evans","year":"2004","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1615","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1620","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp-2012-302444","article-title":"Psychostimulant effect of levodopa: reversing sensitisation is possible","volume":"84","author":"Castrioto","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1625","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mds.29700","article-title":"Management of impulse control and related disorders in Parkinson's disease: an expert consensus","volume":"39","author":"Debove","year":"2024","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1630","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson's disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1635","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/papt.12321","article-title":"Psychological interventions for people with Parkinson's disease in the early 2020s: where do we stand?","volume":"94","author":"Zarotti","year":"2021","journal-title":"Psychol Psychother Theory Res Pract"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1640","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/brainsci12020159","article-title":"Sexual dysfunctions in Parkinson's disease and their influence on partnership: data of the PRISM study","volume":"12","author":"Kinateder","year":"2022","journal-title":"Brain Sci"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1645","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756285611411504","article-title":"Management of sexual dysfunction in Parkinson's disease","volume":"4","author":"Bronner","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1650","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mdc3.12456","article-title":"Sildenafil in the treatment of erectile dysfunction in Parkinson's disease","volume":"4","author":"Bernard","year":"2017","journal-title":"Mov Disord Clin Pract"},{"issue":"7954","key":"10.1016\/j.neurol.2024.11.004_bib1655","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"ON-OFF effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"307","author":"Marsden","year":"1976","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1660","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.26731","article-title":"The hidden sister of motor fluctuations in Parkinson's disease: a review on nonmotor fluctuations","volume":"31","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2016","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1665","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","article-title":"Nonmotor fluctuations in Parkinson's disease: frequent and disabling","volume":"59","author":"Witjas","year":"2002","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1670","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00702-015-1437-x","article-title":"Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS)","volume":"122","author":"Storch","year":"2015","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2024.11.004_bib1675","doi-asserted-by":"crossref","first-page":"1149615","DOI":"10.3389\/fneur.2023.1149615","article-title":"Impact of non-motor fluctuations on QOL in patients with Parkinson's disease","volume":"14","author":"Kakimoto","year":"2023","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1680","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1685","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/aws078","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours","volume":"135","author":"Lhomm\u00e9e","year":"2012","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1690","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial","volume":"17","author":"Lhomm\u00e9e","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1695","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","article-title":"Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study","volume":"89","author":"Abbes","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1700","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","article-title":"Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study","volume":"263","author":"Drapier","year":"2016","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1705","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park Relat Disord"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1710","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3233\/JPD-225112","article-title":"Infusion therapies in the treatment of Parkinson's disease","volume":"13","author":"Van Laar","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2024.11.004_bib1715","series-title":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition","year":"2013"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1720","first-page":"1","article-title":"First delirium episode in Parkinson's disease and parkinsonism: incidence, predictors, and outcomes","volume":"7","author":"Green","year":"2021","journal-title":"npj Park Dis"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1725","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.5270","article-title":"Identifying delirium in Parkinson disease: a pilot study","volume":"35","author":"Lawson","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2024.11.004_bib1730","first-page":"1","article-title":"Delirium after deep brain stimulation in Parkinson's disease","volume":"8885386","author":"Li","year":"2021","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neurol.2024.11.004_bib1735","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.108009","article-title":"Incidence and management of idiopathic peri-lead edema (IPLE) following deep brain stimulation (DBS) surgery: case series and review of the literature","volume":"234","author":"Giordano","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1740","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson's disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1745","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1750","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1474-4422(13)70294-1","article-title":"Mood and behavioural effects of subthalamic stimulation in Parkinson's disease","volume":"13","author":"Castrioto","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1755","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.26434","article-title":"Limbic stimulation drives mania in STN-DBS in Parkinson disease: a prospective study","volume":"92","author":"Prange","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.11.004_bib1760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2021.786166","article-title":"Non-motor adverse effects avoided by directional stimulation in Parkinson's disease: a case report","volume":"12","author":"Alonso-Frech","year":"2022","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1765","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/mds.20501","article-title":"Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation","volume":"20","author":"Witjas","year":"2005","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1770","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1775","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease","volume":"16","author":"Lim","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1780","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/mdc3.13738","article-title":"Course of impulse control disorder symptoms in Parkinson's disease: deep brain stimulation versus medications","volume":"10","author":"Hernandez-Con","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1785","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): Secondary analysis of an open-label randomised trial","volume":"17","author":"Lhomm\u00e9e","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.11.004_bib1790","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fneur.2014.00084","article-title":"Mechanisms of body weight fluctuations in Parkinson's disease","volume":"5","author":"Kistner","year":"2014","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1795","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/brain\/awad324","article-title":"Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease","volume":"147","author":"B\u00e9reau","year":"2024","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1800","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mds.28390","article-title":"Apathy induced by subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis","volume":"36","author":"Zoon","year":"2021","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1805","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awq032","article-title":"Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation","volume":"133","author":"Thobois","year":"2010","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neurol.2024.11.004_bib1810","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois","year":"2013","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.neurol.2024.11.004_bib1815","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00415-006-0177-0","article-title":"Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?","volume":"253","author":"Drapier","year":"2006","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1820","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brs.2020.12.008","article-title":"Structural and functional correlates of subthalamic deep brain stimulation-induced apathy in Parkinson's disease","volume":"14","author":"Boon","year":"2021","journal-title":"Brain Stimul"},{"issue":"21","key":"10.1016\/j.neurol.2024.11.004_bib1825","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.0b013e3181c34b34","article-title":"Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study","volume":"73","author":"Le Jeune","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1830","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.parkreldis.2014.07.013","article-title":"Stimulation of the subthalamic area modulating movement and behavior","volume":"20","author":"Ricciardi","year":"2014","journal-title":"Park Relat Disord"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1835","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jnnp.2002.009803","article-title":"Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease","volume":"75","author":"Funkiewiez","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1840","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/bmjno-2023-000524","article-title":"Subthalamic stimulation has acute psychotropic effects and improves neuropsychiatric fluctuations in Parkinson's disease","volume":"6","author":"Magalh\u00e3es","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.neurol.2024.11.004_bib1845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnhum.2012.00193","article-title":"The other side of the coin: oxytocin decreases the adherence to fairness norms","volume":"6","author":"Radke","year":"2012","journal-title":"Front Hum Neurosci"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1850","doi-asserted-by":"crossref","first-page":"372","DOI":"10.20344\/amp.4928","article-title":"Depression and anxiety following deep brain stimulation in Parkinson's disease: systematic review and meta-analysis","volume":"27","author":"Couto","year":"2014","journal-title":"Acta Med Port"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1855","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11065-015-9302-0","article-title":"Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson's disease: a meta-analysis","volume":"25","author":"Combs","year":"2015","journal-title":"Neuropsychol Rev"},{"issue":"12","key":"10.1016\/j.neurol.2024.11.004_bib1860","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1865","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.58.7.1019","article-title":"Parkinson's disease and sleepiness: an integral part of PD","volume":"58","author":"Arnulf","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1870","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11910-010-0113-7","article-title":"Parkinson's disease dementia","volume":"10","author":"Docherty","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurol.2024.11.004_bib1875","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2018.12.016","article-title":"Resting-state fMRI in Parkinson's disease patients with cognitive impairment: a meta-analysis","volume":"62","author":"Wolters","year":"2019","journal-title":"Park Relat Disord [Internet]"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1880","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00401-007-0193-x","article-title":"Parkinson's disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons","volume":"113","author":"Braak","year":"2007","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-013-0377-9","article-title":"Cholinergic dysfunction in Parkinson's disease","volume":"13","author":"M\u00fcller","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib1890","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Henderson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1895","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/mds.25683","article-title":"Characterizing freezing of gait in Parkinson's disease: models of an episodic phenomenon","volume":"28","author":"Nieuwboer","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1900","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JPD-181306","article-title":"Progression of cognitive decline in Parkinson's disease","volume":"8","author":"Roheger","year":"2018","journal-title":"J Parkinsons Dis"},{"issue":"24","key":"10.1016\/j.neurol.2024.11.004_bib1905","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1910","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000010","article-title":"Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study","volume":"37","author":"Emre","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1915","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2024.11.004_bib1920","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/bs.irn.2017.04.005","article-title":"Psychosis in Parkinson's Disease","author":"Ffytche","year":"2017"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1925","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1930","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1212\/01.WNL.0000145764.70698.4E","article-title":"Visual perception in Parkinson disease dementia and dementia with Lewy bodies","volume":"63","author":"Mosimann","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib1935","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00415-015-7687-6","article-title":"On visual hallucinations and cortical networks: a trans-diagnostic review","volume":"262","author":"Carter","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.11.004_bib1940","first-page":"1","article-title":"Sensorimotor hallucinations in Parkinson's disease","volume":"12","author":"Bernasconi","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurol.2024.11.004_bib1945","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2017.01.014","article-title":"Hallucinations and the spectrum of psychosis in Parkinson's disease","volume":"374","author":"Frei","year":"2017","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1016\/j.neurol.2024.11.004_bib1950","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib1955","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","article-title":"Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors","volume":"16","author":"Seeman","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"9916","key":"10.1016\/j.neurol.2024.11.004_bib1960","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.11.004_bib1965","doi-asserted-by":"crossref","first-page":"105951","DOI":"10.1016\/j.parkreldis.2023.105951","article-title":"Pimavanserin for psychosis in Parkinson's disease dementia: subgroup analysis of the HARMONY Trial","volume":"119","author":"Weintraub","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.neurol.2024.11.004_bib1970","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0891988716640378","article-title":"Quetiapine for psychosis in Parkinson disease and neurodegenerative Parkinsonian disorders","volume":"29","author":"Desmarais","year":"2016","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1975","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-019-09538-z","article-title":"Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis","volume":"267","author":"Martin","year":"2020","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2024.11.004_bib1980","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10113","key":"10.1016\/j.neurol.2024.11.004_bib1985","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.neurol.2024.11.004_bib1990","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1111\/ene.15391","article-title":"The European Academy of Neurology brain health strategy: one brain, one life, one approach","volume":"29","author":"Bassetti","year":"2022","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib1995","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/02692163231214408","article-title":"A systematic practice review: Providing palliative care for people with Parkinson's disease and their caregivers","volume":"38","author":"Garon","year":"2023","journal-title":"Palliat Med"},{"issue":"7","key":"10.1016\/j.neurol.2024.11.004_bib2000","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(23)00129-1","article-title":"Palliative care to support the needs of adults with neurological disease","volume":"22","author":"Kluger","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib2005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mds.28773","article-title":"Access and attitudes toward palliative care among movement disorders clinicians","volume":"37","author":"Miyasaki","year":"2022","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.neurol.2024.11.004_bib2010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.21037\/apm.2017.12.02","article-title":"Palliative care for Parkinson's disease","volume":"7","author":"Ng","year":"2018","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.neurol.2024.11.004_bib2015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00120","article-title":"Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson's disease patients","volume":"9","author":"Klietz","year":"2018","journal-title":"Front Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2024.11.004_bib2020","doi-asserted-by":"crossref","first-page":"E2571","DOI":"10.1212\/WNL.0000000000007552","article-title":"Framing advance care planning in Parkinson disease: patient and care partner perspectives","volume":"92","author":"Lum","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2024.11.004_bib2025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-684X-11-20","article-title":"Clinical aspects of palliative care in advanced Parkinson's disease","volume":"11","author":"Lokk","year":"2012","journal-title":"BMC Palliat Care"},{"issue":"2","key":"10.1016\/j.neurol.2024.11.004_bib2030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/brain\/awad324","article-title":"Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease","volume":"147","author":"B\u00e9reau","year":"2024","journal-title":"Brain"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724006635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724006635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:36:15Z","timestamp":1744288575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724006635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":207,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0035378724006635"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.11.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}